Skip to content
Open access

A step-wise, deterministic and fatal mouse model of myeloid neoplasm with spontaneous acquisition of patient-relevant RTK-RAS mutations.

Sep 2026 · Oncogene · 0 citations · 53 references
Medicine

TL;DR

The specificity for RTK-RAS mutations coupled with ongoing differentiation, reflects clinically relevant biological contexts thus providing a tractable model of myeloid neoplasm for mechanistic studies and drug discovery.

Abstract

Leukaemia arises through the stepwise transformation of healthy haematopoietic cells, yet the asymptomatic premalignant phase and its progression to overt disease remain poorly understood. To model this process, we engineered a patient-derived CEBPA mutation into Hoxb8-FL multipotent murine progenitors and transplanted them into syngeneic mice, capturing a clinically silent premalignant stage. All recipients developed overt disease after ~12 months with 100% penetrance and all acquired secondary RTK-RAS mutations, often with identical amino acid changes to those in patients. Single-cell transcriptomics and phenotypic profiling showed that premalignant mutant cells adopt a plasmacytoid dendritic progenitor-like state in vitro which generates both myeloid and B-lymphoid lineages during premalignancy in vivo, with individual tumours restricted to one lineage. The specificity for RTK-RAS mutations coupled with ongoing differentiation, reflects clinically relevant biological contexts thus providing a tractable model of myeloid neoplasm for mechanistic studies and drug discovery.

Read PDF

Similar papers

Review Open access Sep 2026

Silent, but not innocent: the emerging role of clonal hematopoiesis in predicting therapy-related myeloid neoplasms

Therapy-related myeloid neoplasms (t-MNs), which develop following cytotoxic chemotherapy or radiotherapy, remain one of the most significant clinical challenges in modern hematology due to their aggressive clinical course and poor survival outcomes. The traditional paradigm regarded the development of t-MNs as a conse...

Şerife Emre Ünsal · 0 citations
Open access Sep 2026

Tet2 deficiency drives age-related heterogeneous progression of myeloid neoplasms through epigenetic-immune microenvironment imbalance

A hematopoietic specific Tet2 conditional knockout mouse model recapitulates core clinical features of elderly Tet2-mutated myeloid neoplasms and provides a preclinical platform for mechanistic investigation and the development of epigenetic and immune-targeted precision therapies.

Yan-Xia Chen, Li Yu, Rui Yang et al. · 0 citations
Review Open access Sep 2026

Recent Advances in Chronic Myeloid Leukaemia (CML): Emerging Molecular and Immunotherapeutic Targets.

The pivotal role of LSCs in disease progression and relapse is highlighted, potential molecular and epigenetic regulators as new targets for intervention are evaluated, and the development of combination treatment strategies to improve TFR rates and move towards curative outcomes is supported.

Jing-Yi Dai, Pan-Pan Zheng, Jian Liu et al. · 0 citations
Review Sep 2026

HTLV-1 and ATL: Decoding Molecular Pathogenesis for Next-Generation Therapies.

Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-lymphocyte malignancy arising as a late consequence of human T-cell leukemia virus type 1 (HTLV-1) infection. Despite decades of research, ATL remains characterized by a dismal prognosis and high relapse rates, representing a significant clinical challenge. This r...

Mina Mohammad-rezaei, Zahra Shafaghat, Mina Noroozbeygi et al. · 0 citations
Review Open access Sep 2026

Clonal hematopoiesis of indeterminate potential and cancer immunotherapy: a host-intrinsic immune-inflammatory modifier of treatment efficacy and toxicity

Clonal hematopoiesis of indeterminate potential (CHIP), the age-related expansion of hematopoietic stem cells carrying leukemia-associated somatic mutations, is common in patients with cancer and is increasingly detected during tumor-only genomic profiling and cell-free DNA sequencing. In this narrative review, we asse...

Long-Jun Huang, Jia-Hao Sheng, Lui Chi et al. · 0 citations
Sep 2026

LPCAT3 is essential for leukemia progression and represents a therapeutic vulnerability in AML

RNA-seq following LPCAT3 loss showed that genes differentially expressed were significantly enriched in granulocyte chemotaxis–related pathways, suggesting a role of LPCAT3 in modulation of leukemic differentiation programs and microenvironmental interactions, established that LPCAT3 as a previously unrecognized mediat...

Mu-Tian Cao, L. Cong, Yi-Fei He et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.